Form 8-K · Current Report · Filed 2026-07-10
Crinetics Pharmaceuticals Announces Merger with Vertex Pharmaceuticals
Crinetics Pharmaceuticals, Inc. announced on July 6, 2026, that it has entered into a material definitive agreement for a merger with Vertex Pharmaceuticals Incorporated. The agreement involves the merger of Clark Merger Sub, Inc., a subsidiary of Vertex, with and into Crinetics, with Crinetics surviving as a wholly owned subsidiary of Vertex. As part of the agreement, Crinetics entered into non-compete agreements with key executives, including its President and CEO, R. Scott Struthers, Ph.D., Chief Financial Officer Tobin Schilke, Chief Scientific Officer Stephen Betz, Ph.D., and Chief Commercial Officer Isabel Kalofonos. These agreements prohibit the executives from working for certain restricted businesses for one year post-merger. In consideration for the non-compete agreements, Schilke, Betz, and Kalofonos will receive cash payments of $140,000, $30,000, and $30,000, respectively, on the merger closing date.
- Filer
- Crinetics Pharmaceuticals Inc. CRNX · NASDAQ
- Filed
- Accession
- 0001140361-26-028208
- CIK
- 0001658247
- Signal
- High impactHealthcare
- Source
- Official filing on sec.gov ↗
Items reported
Reported Item
Market reaction
Close before filing
$83.62
Next session
+0.1%
Since filing
-0.1%
Latest close
$83.52
What happened, not what will happen — closing prices around the filing date.
Precedent
Previous filings from CRNX reporting the same item, with the next session's move:
Insider tape
Within 45 days of this filing, CRNX insiders reported 31 Form 4 transactions — net selling of $366K.
About Crinetics Pharmaceuticals Inc.
Crinetics Pharmaceuticals Inc. is a biopharmaceutical company dedicated to the development of novel therapeutics for patients with endocrine conditions and other rare diseases. The primary focus of Crinetics is on crafting oral therapies that target hormone receptors, offering significant potential to transform the treatment landscape for several disorders. The company's pipeline includes investigational drugs such as paltusotine and CRN04894, aimed at addressing conditions like acromegaly and congenital adrenal hyperplasia, respectively. Crinetics combines cutting-edge drug discovery with an in-depth understanding of disease biology to impact the field of endocrinology substantially. By specializing in small molecules, Crinetics Pharmaceuticals seeks to provide new treatment options that enhance patient quality of life and address significant unmet medical needs. Headquartered in San Diego, California, the enterprise collaborates with academic institutions and industry partners to position its innovations at the forefront of medical advancement. Its work holds significant potential to influence the pharmaceutical industry, contributing to the expansion of targeted therapies within niche markets where few options currently exist.
Never miss another CRNX filing
Profitelligence watches EDGAR around the clock and alerts you within seconds.